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A B S T R A C T
Background: The presence of mitral annular calcification (MAC) affects prognosis in patients under-
going transcatheter aortic valve implantation (TAVI). MAC frequently coexists with calcifications of 
mitro-aortic continuity (CMAC). 
Aims: We aimed at qualitative and semi-quantitative analysis of calcifications of the mitral complex 
— MAC and CMAC in multi-slice computed tomography, in order to assess their impact on the occur-
rence and dynamics of mitral regurgitation (MR) following TAVI. 
Methods: The study group consisted of 94 patients (mean [SD] age was 79.9 [8.02] years; 67.1% female). 
Agatston scale — Calcium Score was used for quantitative analysis. MAC and CMAC were also assessed 
semi-quantitatively as either non-severe or severe. MR following TAVI was defined as unchanged, im-
proved or worsened by at least one degree. 
Results: Patients with MAC (59.6%) had higher mean aortic gradients (P = 0.02) and smaller left ven-
tricular diastolic diameter (P = 0.002). Patients with CMAC (48.9%) had higher Calcium Score aortic 
valve (P = 0.006). After TAVI MR improved in 17 (18.1%) patients and worsened in 7 (7.5%) patients. In 
multivariable logistic regression analysis MR worsening was associated with higher CMAC (OR, 1.092; 
95% CI, 1.006–1.185; P = 0.03), as well as bicuspid aortic valve (OR, 6.348; 95% CI, 1.048–38.436; P = 0.04). 
Conclusions: CMAC was associated with MR worsening following TAVI. This is of relevance in procedural 
planning in patients with severe aortic stenosis (AS) and coexisting MR in whom arguments for and 
against surgical repair of concomitant mitral insufficiency are considered.
Key words: aortic stenosis, calcification of mitro-aortic continuity, mitral annular calcification, mitral 
regurgitation, transcatheter aortic valve implantation 
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INTRODUCTION
Mitral annular calcification (MAC) occurs as a result of 
a chronic degenerative process of the fibrous support struc-
ture of the mitral valve. MAC is present in approximately 
8%–15% of the general population, more often in women 
[1–3]. MAC commonly coexists with aortic stenosis (AS) [4, 
5] and may have similar etiology and pathophysiological 
mechanism [6, 7]. About one-fifth of patients with mild to 
moderate AS and half with severe AS have at least some 
degree of MAC [4, 8]. Half of all patients undergoing tran-
scatheter aortic valve implantation (TAVI) have MAC, and 
approximately 20% have severe MAC [8–11]. The latter is 
associated with increased all-cause and cardiovascular 
mortality and with conduction abnormalities in patients 
undergoing TAVI [10, 11]. Several studies assessed the role 
of mitral regurgitation (MR) following TAVI [12, 13], but only 
few examined the influence of MAC on its changes after 
TAVI [8, 11, 14, 15]. MAC frequently coexists with calcifica-
tion of mitro-aortic continuity (CMAC) [16]. The latter may 
influence the results of TAVI, especially in the case of deeper 
implantation, protruding to left ventricular outflow tract 
(LVOT). To the best of our knowledge, the role of CMAC on 
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W H A T ’ S  N E W ?
Aortic valve calcifications in patients with aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) are 
frequently accompanied by calcifications of mitro-aortic continuity (CMAC). Their presence is frequently disregarded and not 
included in the qualitative and semi-quantitative analyses of calcifications of the aortic-mitral complex. We have demonstrated 
that the presence of CMAC was associated with mitral regurgitation (MR) worsening after TAVI. This is a novel finding, which 
may be of relevance for procedural planning, in particular in patients with severe AS and coexisting MR in whom arguments for 
and against surgical repair of concomitant mitral insufficiency are considered, as opposed to isolated aortic valve procedure.
the occurrence and dynamic changes of MR during TAVI 
procedure has never been examined.
In the present study we aimed at qualitative and 
semi-quantitative analysis of calcifications of the mitral 
complex — MAC and CMAC in multi-slice computed to-
mography (MSCT) in patients qualified to TAVI, in order to 
assess their impact on the occurrence and dynamics of MR 
following aortic valve implantation. 
METHODS
Study group
We retrospectively examined 94 consecutive patients with 
severe AS who underwent TAVI procedure at the Institute 
of Cardiology in Warsaw, between January 2016 and De-
cember 2017. The study protocol was approved by the local 
Bioethics Committee. All examined patients presented 
severe symptomatic AS and had been disqualified from 
surgical aortic valve replacement by an institutional Heart 
Team. Informed consent for diagnostic and treatment 
procedures was obtained from all patients.
Before TAVI, all patients underwent routine laboratory 
testing, transthoracic echocardiography (TTE), coronary 
angiography, MSCT as well as angio-MSCT of iliac and 
femoral arteries [17]. Aortic valve anatomy and diameter 
were evaluated by TTE and MSCT [18]. These studies were 
used for proper planning of the valve implantation in terms 
of selection of access route, valve size, and complication 
risk assessment. 
Multi-slice computed tomography 
Before TAVI procedure, all patients underwent MSCT 
with and without contrast. MSCT was performed using 
a dual-source third generation scanner, Somatom Force 
(Siemens Healthcare, Forchheim, Germany). CT acquisi-
tion parameters were: slice collimation 2 × 192 × 0.6 mm, 
384 layers, gantry rotation time 250 ms, tube voltage 
80–120 kV, tube current 320–500 mAs (depending on the 
patient body mass). 
A prospective ECG gated non-contrast scan was per-
formed to measure the Calcium Score of the aortic valve 
and mitral annulus. MAC and CMAC were evaluated in 
MSCT after contrast administration.
MSCT with contrast was routinely performed in patients 
before TAVI for evaluation of coronary arteries and access to 
TAVI (entire aorta and iliofemoral arteries). A bolus of 70 to 
100 ml (depending on the patient body mass) of iodinated 
contrast media (Ultravist 370 Bayer Pharma AG) was admin-
istered through an antecubital vein at a rate of 4.0 ml/s.
Quantitative assessment of aortic valve calcifications 
was done using the Agatston scale — Calcium Score aor-
tic valve [19, 20]. MAC was evaluated quantitatively and 
semi-quantitatively and CMAC was assessed semi-quan-
titatively.
MAC was defined as the presence of dense calcium 
deposits at the base of mitral leaflets at the level of the 
mitral annulus. The quantitative assessment of calcifica-
tions — Calcium Score mitral annulus — was done using 
the Agatston scale based on the maximum X-ray absorp-
tion coefficient measured in Hounsfield units (HU) and the 
measurement of the calcium deposits size. The absorbing 
structures were considered to be 130 HU and more.
MAC was assessed in cross-sectional view parallel to 
the plane of the mitral annulus and rated in the semi-quan-
titative scale, depending on the degree of annular involve-
ment, in the following way: 0, no calcifications; 1, mild 
calcifications (less than one-third of the circumference 
of the annulus involved); 2, moderate calcifications (be-
tween one-third and half of the annulus circumference); 
3, severe calcifications (more than half of the annulus 
circumference), according the methodology adopted by 
others [11, 21]. 
CMAC was defined as the presence of calcifications lo-
calized in the posterior aspect of LVOT — in the continuity 
between the base of anterior mitral leaflet/mitral annulus 
and non-coronary aortic cusp. Calcifications localized in the 
posterior (CMAC) and anterior aspect of LVOT are shown 
on Figure 1. 
CMAC was evaluated semi-quantitatively in sagittal 
oblique view and assessed along the maximum length of 
calcification. CMAC was rated depending on the length of 
calcifications in the largest dimension the following way: 
0, no calcifications; 1, mild calcifications (less than 3 mm); 
2, moderate calcifications (3–8 mm); 3, severe calcifica-
tions (over 8 mm); according the methodology adopted 
by others [10].
Subsequently, patients were classified in a dichoto-
mous manner as having non-severe or severe MAC and 
CMAC (grades 0, 1, and 2 versus grade 3). Classification 
was performed by a single observer, experienced in the 
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assessment of pre-TAVR CT scans, blinded to the clinical 
and other imaging data.
Echocardiography
All patients underwent TTE (Vivid E95, Vivid S70) prior to 
the procedure, either during the same or preceding hos-
pitalization, as part of diagnostic routine assessment. The 
follow-up transthoracic echocardiographic examination 
was routinely performed before discharge following TAVI 
procedure and up to 30 days after TAVI.
MR was evaluated in an integrated manner, according 
to a current standard, based on color Doppler jet area, vena 
contracta, proximal isovelocity surface area, effective regur-
gitant orifice [22, 23], and graded as: 0, no MR; 1, mild MR; 
2, moderate MR; 3, severe MR; with significant MR defined 
as grade ≥2. Changes of MR severity following TAVI were 
defined as no change, improvement, or worsening by at 
least one degree. 
Statistical analysis
Continuous variables with normal distribution were pre-
sented as means with their standard deviations, and in the 
case of non-normally distributed variables (as confirmed 
by the Kolmogorov-Smirnov test), in the form of the me-
dian and the interquartile range. Categorical variables 
were expressed as percentages. Patients were divided 
into groups with severe vs non-severe/absent MAC and 
CMAC, as previously defined. Comparative analyzes of 
continuous variables were done using the Student t-test 
or the Mann-Whitney tests, and of discrete variables using 
the chi-square test.
In order to evaluate if the degree of calcification of mi-
tral complex affects MR in patients undergoing TAVI, single- 
and multi-variable logistic regression analyses were used. 
A univariate logistic regression analysis was performed 
to obtain the odds ratio for worsening MR after TAVI. 
The following variables were used in univariate models: 
age, female sex, clinical factors (hypertension, coronary 
artery disease, diabetes mellitus, atrial fibrillation, chronic 
renal failure, estimated glomerular filtration rate [eGFR]), 
echocardiographic parameters (left ventricular diastolic 
diameter, left ventricular systolic diameter, interventricular 
septal, ejection fraction, LVOT, aortic root, maximum aortic 
gradient, mean aortic gradient), bicuspid aortic valve (BAV), 
Calcium Score aortic valve, Calcium Score mitral annulus, 
CMAC and MAC.
Thereafter, a multivariable logistic regression analysis 
was performed using the variables with P-values <0.10 in 
the univariate analyses, to examine their independent 
association with MR worsening after TAVI. Results of the 
regression model were presented as odds ratios, with 
95% confidence intervals. A P-value <0.05 was considered 
statistically significant. All analyses were performed using 
SAS 9.2. 
RESULTS
The study group consisted of 94 patients (63 female 
[67.1%]), undergoing TAVI. The mean (SD) age of patients 
was 79.9 (8.02) years. Clinical characteristics and echocardi-
ographic parameters of the studied patients are presented 
in Table 1. Examples of MAC and CMAC in MSCT are shown 
in Figure 2 and Figure 3.
Table 1. Baseline characteristics of the study group
Characteristics of patients (n = 94)
Age, years, mean (SD) 79.86 (8.02)
Female sex, n (%) 63 (67.1)
Hypertension, n (%) 76 (80.8)
Diabetes mellitus, n (%) 34 (36.2)
Coronary artery disease, n (%) 52 (55.3)
Chronic lung disease, n (%) 15 (16.0)
Atrial fibrillation, n (%) 39 (41.5)
NYHA functional class III, n (%) 28 (29.8)
NYHA functional class IV, n (%) 3 (3.2)
eGFR, ml/min, mean (SD) 58.30 (18.67)
BAV, n (%) 23 (25.6)
Pacemaker before TAVI, n (%) 16 (17.2)
LVDD, mm, mean (SD) 48.14 (7.90)
LVDS, mm, mean (SD) 31.11 (9.54)
IVDS, mm, mean (SD) 14.53 (2.42)
EF, %, mean (SD) 55.12 (13.27)
Maximum aortic gradient, mm Hg, mean (SD) 83.58 (22.67)
Mean aortic gradient, mm Hg, mean (SD) 51.13 (14.33)
AVA, cm2, mean (SD) 0.66 (0.18)
Aortic annulus TTE, mm, mean (SD) 22.99 (2.15)
Aortic root, mm, mean (SD) 31.53 (4.00)
Calcium Score mitral annulus, HU, median (IQR) 161 (0–3016)
Calcium Score aortic valve, HU, median (IQR) 3416  
(856.8–8868)
Abbreviations: AVA, aortic valve area; BAV, bicuspid aortic valve; EF, ejection 
fraction; eGFR, estimated glomerular filtration rate; HU, Hunsfield units; IVDS, in-
terventricular septal; LVDD, left ventricular diastolic diameter; LVDS, left ventricular 
systolic diameter; NYHA, New York Heart Association; SD, standard deviation; TAVI, 
transcatheter aortic valve implantation; TTE, transthoracic echocardiography
Figure 1. Comparison of calcifications localized in the anterior 
and posterior aspect of the left ventricular outflow tract in oblique 
sagittal projection on multislice computed tomography
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MAC
Median and the interquartile range of Calcium Score mi-
tral annulus was 161 (0–3016) HU. Fifty six (59.6%) out of 
94 patients had MAC. Mild MAC was present in 25 patients 
(26.7%), moderate MAC in 10 patients (10.6%), and severe 
MAC in 21 patients (22.3%).
MAC was more prevalent in females (82.1% vs 44.7%; 
P <0.001) compared to patients without MAC. Patients 
with MAC had higher mean aortic gradients (mean [SD] 
54.07 [13.62] mm Hg vs 46.79 [14.42] mm Hg; P = 0.02) 
and smaller left ventricular diastolic diameter (mean [SD] 
46.09 [6.86] mm vs 51.19 [8.42] mm; P = 0.002) and trend to 
older patients (mean [SD] 81.09 [7.56] years vs 78.05 [8.42] 
years; P = 0.07) compared to patients without MAC. Com-
parison of selected variables in patients with no/non-severe 
MAC versus severe MAC is presented in Table 2. 
CMAC
Almost half of the patients (46 [48.9%]) had CMAC. Mild 
CMAC was present in 21 patients (22.3%), moderate 
CMAC in 13 patients (13.8%), and severe CMAC in 12 pa-
tients (12.8%). Patients with CMAC had higher Calcium 
Score aortic valve (mean [SD] 3773.67 [1734.02] HU vs 
2875.1 [1352.76] HU; P = 0.006) and a trend to smaller aortic 
valve area (AVA) (mean [SD] 0.59 [0.16] cm2 vs 0.66 [0.20] 
cm2; P = 0.05) compared to patients without CMAC. 
Table 2. Baseline characteristic of patients with and without severe mitral annular calcification, as well as with and without severe calcifica-
tion of mitro-aortic continuity (n = 94)
Non severe 
MAC (n = 73)
Severe MAC 
(n = 21)
P-value Non severe 




Age, years, mean (SD) 78.79 (8.01) 83.57 (7.00) 0.01 80.32 (7.65) 76.75 (9.99) 0.15
Female sex, n (%) 46 (63.0) 17 (80.9) 0.12 52 (63.4) 11 (91.7) 0.09
Hypertension, n (%) 58 (79.4) 18 (85.7) 0.75 66 (80.5) 10 (83.3) 1.00
Coronary artery disease, n (%) 39 (53.4) 13 (61.9) 0.49 48 (58.5) 4 (33.3) 0.10
Diabetes mellitus, n (%) 29 (39.7) 5 (23.8) 0.18 30 (36.6) 4 (33.3) 1.00
Atrial fibrillation, n (%) 33 (54.8) 6 (28.6) 0.17 35 (42.7) 4 (33.3) 0.76
Chronic lung disease, n (%) 13 (17.8) 2 (9.5) 0.51 14 (17.1) 1 (8.3) 0.68
eGFR, ml/min, mean (SD) 57.57 (19.12) 60.84 (17.22) 0.48 58.73 (18.62) 55.4 (19.59) 0.57
BAV, n (%) 21 (30.0) 2 (10.0) 0.07 16 (20.2) 7 (63.6) 0.005
LVDD, mm, mean (SD) 49.35 (8.05) 44.05 (5.82) 0.006 48.41 (8.06) 46.18 (6.57) 0.38
LVDS, mm, mean (SD) 32.25 (10.17) 26.57 (4.50) 0.04 30.79 (9.73) 36.5 (2.12) 0.42
IVDS, mm, mean (SD) 14.17 (2.07) 15.80 (3.12) 0.04 14.51 (2.31) 14.64 (3.23) 0.87
EF, %, mean (SD) 53.75 (14.20) 59.76 (8.14) 0.02 55.35 (13.70) 53.45 (9.81) 0.66
LVOT, mm, mean (SD) 21.54 (2.08) 20.25 (1.48) 0.01 21.43 (2.06) 20.17 (1.40) 0.01
Aortic annulus TTE, mm, mean (SD) 23.20 (2.25) 22.00 (1.45) 0.006 23.09 (2.21) 21.92 (1.38) 0.02
Aortic root, mm, mean (SD) 31.79 (3.88) 30.63 (4.41) 0.27 31.47 (3.87) 32.00 (5.10) 0.69
AVA, cm2, mean (SD) 0.80 (0.15) 0.66 (0.05) 0.01 0.78 (0.14) 0.63 (0.04) 0.008
Maximum aortic gradient, mm Hg,  
mean (SD)
82.48 (22.42) 87.38 (23.68) 0.39 83.52 (23.78) 83.96 (13.49) 0.92
Mean aortic gradient, mm Hg, mean (SD) 50.42 (14.09) 53.60 (15.24) 0.37 50.86 (14.97) 52.97 (9.11) 0.64
RVSP, mm Hg, mean (SD) 47.15 (14.73) 40.92 (8.81) 0.06 46.80 (14.03) 39.43 (12.80) 0.19
Pulmonary hypertension, n (%) 33 (45.2) 8 (38.1) 0.56 38 (47.8) 3 (25.0) 0.16
Calcium Score mitral annulus, HU, 
median (IQR)
0 (0–460.7) 5661  
(4008–7598)
<0.0001 139.4 (0–2324) 689.7 
(149–4040)
0.18
Calcium Score aortic valve, HU,  
mean (SD)/median (IQR)





Abbreviations: AVA, aortic valve area;  BAV, bicuspid aortic valve; CMAC, mitro-aortic continuity; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HU, Hunsfield 
units; IVDS, interventricular septal; LVDD, left ventricular diastolic diameter; LVDS, left ventricular systolic diameter; LVOT, left ventricular outflow tract; MAC, mitral annular 
calcification; RVSP, right ventricular systolic pressure; SD, standard deviation; TTE, transthoracic echocardiography
Figure 2. Comparison of reconstruction views showing non-severe 
mitral annular calcification (A) and severe mitral annular calcifica-
tion (B) in sectional view parallel to the mitral annular on multislice 
computed tomography
Figure 3. Comparison of reconstruction views showing non-severe 
calcifications of mitro-aortic continuity (A) and severe calcifications 
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Comparison of selected variables in patients with no/non-se-
vere CMAC versus severe CMAC is presented in Table 2. 
Association between MAC/CMAC and mitral 
regurgitation following TAVI
Before TAVI 64.9% of patients had mild or no MR (grades 
1 or 0) and 35.1% of the patients had more than mild MR 
(grades 2 or 3). After TAVI 77.6% of patients had mild or 
no MR (grades 1 or 0). Patients with higher degrees of MR 
before TAVI had lower ejection fraction (EF) (mean [SD] 49% 
[15.12%] vs 58.38% [10.96%]; P = 0.003) as well as more fre-
quent pulmonary hypertension (60.6% vs 34.3%; P = 0.01). 
Calcium Score mitral annulus (P = 0.34), Calcium Score 
aortic valve (P = 0.59), MAC (P = 0.15) and CMAC (P = 0.70) 
were similar in patients with and without significant MR 
at baseline. MR improved by at least one grade following 
TAVI in 17 (18.1%) patients and worsened by at least one 
grade in 7 (7.5%). 
Patients in whom MR improved after TAVI had diabetes 
mellitus more frequently (58.8% vs 31.2%; P = 0.03) and had 
a trend to lower baseline EF (mean [SD] 49.71% [12.92%] 
vs 56.35% [13.13%]; P = 0.06). Patients in whom MR wors-
ened after TAVI more frequently had BAV (71.4% vs 21.7%; 
P = 0.01) and CMAC (P = 0.03). 
The results of univariate logistic regression analysis 
of factors influencing MR worsening following TAVI are 
presented in Table 3. In multivariable logistic regression 
analysis, MR worsening was associated with higher CMAC 
(OR, 1.092; 95% CI, 1.006–1.185; P = 0.03), as well as the 
presence of BAV (OR, 6.348; 95% CI, 1.048–38.436; P = 0.04).
DISCUSSION
MAC and CMAC are frequent in severe aortic valve steno-
sis. In our study, MAC and CMAC were present in approxi-
mately half of the patients undergoing TAVI. In our series, 
MR severity changed following TAVI, as also described by 
others [8, 11–13, 24, 25]. 
Female sex, higher transvalvular gradient, and older 
age were more frequently present in patients with MAC, 
which is consistent with previous reports [4, 26]. Anatomic 
features, important from diagnostic and procedural point 
of view, such as narrower aortic annulus and LVOT and 
thicker interventricular septum, were associated with 
severe MAC. Conversely, other conditions frequently re-
ported as risk factors for MAC (e.g, hypertension, diabetes 
mellitus, advanced kidney disease, atrial fibrillation) were 
not independent predictors in our population, perhaps 
due to smaller numbers and preselection of patients with 
AS [2, 27]. Only few studies examined the influence of MAC 
on the degree of MR after TAVI, with discordant results 
[8, 11, 14, 15]. In some series MAC was associated with 
worsening of MR [8, 14, 15]. Other authors did not report 
such relationship [11]. We did not observe differences in 
the degree of MR after TAVI in patients with and without 
MAC; however, the number of patients in whom the MR 
worsened was small. 
In contrast to the relatively well defined role of MAC 
in patients with AS, including those undergoing TAVI, 
little is known about the potential role of CMAC in these 
patients. We demonstrated a correlation between CMAC 
and higher Calcium Score aortic valve, thicker ventricular 
septum, narrower aortic annular and LVOT diameters, 
smaller AVA, as well as female sex. These are important 
endpoints, relevant both to the diagnosis of severe AS, 
and to procedural issues, such as valve sizing, as well as 
prognosis [28]. A closer look at CMAC in larger datasets is 
necessary in order to better establish its influence on the 
procedure and its long term results. 
The presence or absence of CMAC in patients with 
MAC may offer explanation to the discordant results of the 
studies examining the influence of MAC on the degree of 
MR after TAVI. Previous studies did not clearly distinguish 
between MAC and CMAC. In our study however, in con-
trast to MAC, the presence of CMAC was an independent 
predictor of worsened MR. To the best of our knowledge, 
this study is the first in which the role of CMAC in MR de-
velopment was assessed. This is an important and novel 
finding, that may have implications in clinical practice. 
CMAC influences both LVOT geometry and mitral valve 
function. Theoretically, the presence of CMAC, working 
as a rigid scaffold, may limit potentially favorable reverse 
remodeling of mitral valve apparatus related to improved 
left ventricular function following TAVI.
Table 3. Univariable logistic regression analysis: factors indepen-
dently associated with MR worsening after TAVI
Variables Univariable logistic regression 
analysis
OR (95% CI) P-value
Age, years 0.96 (0.88–1.05) 0.41
Female sex 1.58 (0.33–7.54) 0.68
Hypertension 0.56 (0.10–3.17) 0.62
Coronary artery disease 0.58 (0.12–2.76) 0.69
Diabetes mellitus 1.35 (0.28–6.45) 0.70
Atrial fibrillation 1.98 (0.42–9.34) 0.44
eGFR, ml/min 0.99 (0.95–1.03) 0.71
BAV 9.03 (1.64–50.46) 0.01
LVDD, mm 1.03 (0.94–1.13) 0.52
LVDS, mm 0.97 (0.83–1.12) 0.65
IVDS, mm 1.12 (0.82–1.52) 0.49
EF, % 0.99 (0.93–1.04) 0.64
LVOT, mm 0.89 (0.60–1.34) 0.59
Aortic annulus TTE, mm 1.08 (0.77–1.52) 0.65
Aortic root, mm 1.148 (0.966–1.363) 0.11
Maximum aortic gradient,  
mm Hg 
1.01 (0.98–1.05) 0.54
Mean aortic gradient, mm Hg 1.02 (0.96–1.08) 0.49
Calcium Score mitral annulus, HU 0.94 (0.76–1.16) 0.55
Calcium Score aortic valve, HU 2.47 (0.46–13.27) 0.29
CMAC ≥2, 3a 1.10 (1.02–1.19) 0.01
MAC ≥2a 0.56 (0.06–4.92) 1.00
aGrades of calcifications: 1, mild; 2, moderate; 3, severe.
Abbreviations: BAV, bicuspid aortic valve; CI, confidence interval; CMAC, mitro-aor-
tic continuity; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HU, 
Hunsfield units; IVDS, interventricular septal; LVDD, left ventricular diastolic diame-
ter; LVDS, left ventricular systolic diameter; LVOT, left ventricular outflow tract; MAC, 
mitral annular calcification; OR, odds ratio; TTE, transthoracic echocardiography
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The presence of CMAC may also influence prosthetic 
valve positioning and expansion, indirectly affecting also 
anterior mitral valve leaflet movement restriction. This is 
probably especially relevant in case of self-expandable 
valves protruding to a greater extend to LVOT, as valve 
implantation depth is related to the presence of MR [29].
In our series, lower LV ejection fraction predicted MR 
improvement. This was also observed by others [15, 30, 
31]. Apart from reduced retrograde transmitral gradient, 
improvement of MR in patients with lower EF (also within 
normal limits) may be partially explained by the removal 
of afterload mismatch following TAVI [32], as acute im-
provement in MR reported following TAVR was related 
to immediate post-procedural changes in left ventricular 
hemodynamics and improved mitral leaflet tethering, 
resulting from reduced afterload [33]. In our patients, as 
in the other series, MR worsened following TAVI only in 
a minority of patients [34–37].
Study limitations
The main limitation of the present study is that it represents 
a retrospective, single-center experience. The relatively 
small population, allowed only for hypothesis generat-
ing results.
CONCLUSIONS
The study demonstrated that CMAC was prevalent in pa-
tients undergoing TAVI and associated with MR worsening. 
This is a novel finding, which may be of relevance for pro-
cedural planning and prevention of implantation failure. 
Its presence is of particular importance in patients with 
severe AS and coexisting MR in whom arguments for and 
against surgical repair of concomitant mitral insufficiency 
are considered, as opposed to isolated aortic valve proce-
dure. Severe CMAC may be an additional argument to con-
sider bivalvular cardiac surgery in patients with equivocal 
MR accompanying AS, rather than isolated percutaneous 
aortic procedure. 
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